VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development

Welcome to VacciTalks by Alira Health – exclusive educational appointments with the leading vaccine experts.

Multimedia
Category:
Published on:
May 10, 2022

For private companies, vaccine development is difficult, risky and takes time and money. Only a few candidates will reach the market and will help to protect patients. Companies are in severe competition to develop and bring their final vaccine products into the supply chain. In the second episode of VacciTalks, together with vaccine expert Roberto Camerini we peeked behind the scenes of vaccine development and get a unique insider look at vaccine development. We discussed difficulties, hurdles, and bottlenecks that vaccine produces face during the vaccine development and even after the product is delivered to the market and ways to overcome them.

During this VacciTalk you can learn:

  • How to set up a pipeline for a vaccine candidate
  • How to navigate process difficulties and prevent bottlenecks
  • Why partners, support, collaboration, and funding are essential
  • Market outlook and prospects for newly developed vaccines

In the course of his career, Roberto has held important management roles in Research and Development for international pharmaceutical groups (Abbott, Serono, Sigma-tau, Alfa-Wassermann, Alfasigma, Cosmo) where he was involved in the development and registration of new molecules and biological products in different therapeutic areas.

He served as Board Director of Sciclone Pharmaceutical Inc. and he is also co-founder and member of the board of directors of the Nibit Foundation (Italian Network for the Biotherapy of Tumors).

Roberto graduated cum laude in Medicine and Surgery at University of Rome “La Sapienza” and specialized with full marks in Liver and Metabolic Diseases at the same University.

Roberto is currently the Medical Director of ReiThera Srl.

Our hosts 

Bernd Schollmeier, Vice President, Global Market Access Vaccines 
Bernd Schollmeier

A vaccine expert with more than 30 years of experience, Bernd has been responsible for a range of global pricing and market access initiatives for vaccines in the international pharmaceutical companies — from delivering a range of solutions across development and strategic market access considerations for trial design to value demonstration in P&R negotiations as well as commercialization strategies.

 

Kenny Carberry, Associate Director, Clinical Development 
Kenny Carberry

Kenny’s background covers a wide array of indications across pharma, medical devices, and digital health. He has multiple years of experience in clinical trial operations and management and offers a unique perspective on the clinical development lifecycle from generating a comprehensive strategy through executing a successful trial.

 

About VacciTalks

VacciTalks is a series of unique appointments with the Key Opinion Leaders of the vaccine world. During each of the episodes, our hosts Bernd Schollmeier and Kenny Carberry will sit down with their guests and talk about the topics that disrupt the vaccine world right now – from development challenges to COVID-19 impact, new technologies, and much more.  

Follow us on LinkedIn and never miss the next VacciTalk!  

Related news

Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Blog April 17, 2023
Pharmaceutical Market Access in the UK: A Changing Landscape
Start reading this interview with Rachel Fyson to gain insight into the changing landscape of market access in the United Kingdom.
Market Access Pharma UK
Blog April 14, 2023
Lifecycle Optimization: The Path to Commercial Success
Pharmaceutical and biotech companies constantly focus on product innovation. But how can you also increase your effectiveness in order to be as commercially competitive and efficient as possible?
Market Access MedTech Pharma
News April 5, 2023
Alira Health Joins EMIG to Advance Market Access in the UK
We are pleased to announce that Alira Health has joined the Ethical Medicines Industry Group (EMIG), a multi-stakeholder network and trade association that represents the interests(...)
Market Access Patient Centricity UK
Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Italy Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence (RWE)
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.